<dl id="ilis8"></dl><strike id="ilis8"><option id="ilis8"><em id="ilis8"></em></option></strike>
<cite id="ilis8"><option id="ilis8"></option></cite>
    1. <ul id="ilis8"></ul>
  1. <blockquote id="ilis8"><strong id="ilis8"></strong></blockquote>
    歡迎光臨:萊耀標準品網(wǎng)!
    ?您的位置:對照品 > 標準品 > 分析標準品 >
    N1-(5-chloropyridin-2-yl)-N2-((1S,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahy
    產(chǎn)品基本信息
    產(chǎn)品編號:C381205
    產(chǎn)品名稱:N1-(5-chloropyridin-2-yl)-N2-((1S,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahy
    產(chǎn)品CAS:1255529-27-1
    規(guī)格含量:5mg
    產(chǎn)品價格:面議
    聯(lián)系我們:
    產(chǎn)品詳細介紹
    標準品編號: C381205
    名稱: N1-(5-chloropyridin-2-yl)-N2-((1S,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide
    別名: N-(5-Chloropyridin-2-yl)-N'-[(1S,2S,4S)-4-[(dimethylamino)carbonyl]-2-[[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]ethanediamide
    CAS號: 1255529-27-1
    分子式: C??H??ClN?O?S
    分子量: 548.06
    類別: Standards; Pharmaceutical/API Drug Impurities/Metabolites;
    應用: N1-(5-chloropyridin-2-yl)-N2-((1S,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamideis a diastereomer of Edoxaban (E555520), an anticoagulant drug which acts as a direct factor Xa inhibitor. N1-(5-chloropyridin-2-yl)-N2-((1S,2S,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamidecan be used as apharmaceuticalstandard for detecting impurities in drugs.
    參考文獻


    2011-2018 信陽萊耀生物科技有限公司 @ 信陽埃爾文生物科技有限公司版權(quán)所有

    中檢所標準品,對照品,標準氣體
    Keywords: 中檢所標準品 對照品 標準氣體
    <dl id="ilis8"></dl><strike id="ilis8"><option id="ilis8"><em id="ilis8"></em></option></strike>
    <cite id="ilis8"><option id="ilis8"></option></cite>
      1. <ul id="ilis8"></ul>
    1. <blockquote id="ilis8"><strong id="ilis8"></strong></blockquote>
      娇妻玩4p被三个男人玩 | 91日皮| 亚洲最大的成人网站4438 | 挨操必网站| 美女被操网站在线观看 |